Gujarat Global News Network, Ahmedabad
Once a daily insulin with flexibility of timing has been introduced in India.
Tresiba, is for type 1 and 2 diabetes patients and has duration of action beyond 42 hours.
Diabetes is rising rapidly in India and is more prevalent among young people of less than 40, said Vinay Ransiwal, Director Market Affairs, Novo Nordisk India. This company has launched the product.
The main advantage of Tresiba is that it allows flexibility in day-to-day dosing time without comprising efficacy or risk of hypoglycaemia. He said that the product has received good response in other countries. The price for the insulin is yet to be decided and it will be made available in a pre filled pen with a easy touch button to release doses.
For news in Hindi see our news daily Chaupal Chronicle